In a 2026 industry outlook interview, Laine Mello, Ecolab Life Sciences, explains how next-gen therapies, digitalization, and ...

While helping care for cancer patients in Steamboat Springs for 19 years, oncologist and hematologist Dr. Robert Rifkin has ...

Bunnie XO shares her harrowing experience with an experimental weight-loss drug, describing severe depression and suicidal ...

Berger has participated in meetings (lectures, advisory boards, consultations) sponsored and compensated by pharmaceutical ...

In an interview with Targeted Oncology, George Mulligan, PhD, discussed the key takeaways from analysis of the Immune Atlas ...

Good Samaritan Hospital in San Jose is charging ahead with a $1.3 billion, multi-phase expansion that hospital and city ...

If winning gold medals were the only standard, almost all Olympic athletes would be considered failures. A clinical psychologist with the United States Olympic and Paralympic Committee, Emily Clark's ...

Charalampos Kostoulas' stoppage-time overhead kick goal delivered a Brighton & Hove Albion a well-earned point from a 1-1 ...

The pilot program allows an AI system to renew a limited list of routine medications for patients without requiring an ...

Ianalumab targets the BAFF receptor, depleting malignant B cells and enhancing ibrutinib's efficacy, offering a potential ...

Few companies stand better poised than Beam Therapeutics to reap the first fruits of the FDA’s promised flexibility toward cell and gene therapies. | Riding a regulatory win for its base editing ...

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...